Abstract：
Individuals with Down syndrome (DS) or Autism Spectrum Disorder (ASD), and especially those with both DS and co-occurring ASD (DS + ASD) commonly display behavioral and psychiatric symptoms that can impact quality of life and places increased burden on caregivers. While the mainstay of treatment in DS and ASD is focused on educational and behavioral therapies, pharmacological treatments can be used to reduce symptom burden. There is a paucity of evidence and limited clinical trials in DS and DS + ASD. Some scientific evidence is available, primarily in open label studies and case series that can guide treatment choices. Additionally, clinical decisions are often extrapolated from evidence and experience from those with ASD, or intellectual disability in those without DS. This article reviews current research in pharmacological treatment in DS, ASD, and DS + ASD, reviews co-occurring neurodevelopmental and mental health diagnoses in individuals with DS + ASD across the lifespan, and describes practical approaches to psychopharmacological management.
摘要：
患有唐氏综合症（DS）或自闭症谱系障碍（ASD）的人，尤其是同时患有DS和同时发生的ASD（DSASD）的患者通常表现出行为和精神症状，这些症状可能会影响生活质量，并增加护理人员的负担。虽然DS和ASD的治疗主要集中在教育和行为疗法上，药物治疗可用于减轻症状负担。DS和DS+ASD的证据很少，临床试验也很有限。有一些科学证据,主要是在开放标签研究和病例系列中，可以指导治疗选择。此外,临床决策通常是从ASD患者的证据和经验中推断出来的，或没有DS的智力残疾。本文就目前DS的药物治疗研究进行综述,ASD,和DS+ASD，回顾了DS+ASD患者在整个生命周期中共同发生的神经发育和心理健康诊断，并描述了心理药理学管理的实用方法。
